Skip to content
OpenCapital
Get started

Cardiff Oncology CRDF Q4 2024 Annual earnings

Reported February 27, 2025 · After market close

Revenue$151.0KBeat by $56.8KDiluted EPS-$0.21Beat by $0.05
Revenue estimate$94.2K
EPS estimate-$0.26

Next report

Aug 4, 2026 (In 3 weeks)
Revenue estimate$62.8K
EPS estimate-$0.17

Versus estimates

Revenue

Q1 2026$41.0KMiss by $47.6KQ4 2025$243.0KBeat by $139.5KQ3 2025$120.0KBeat by $16.5KQ2 2025$121.0KBeat by $11.6KQ1 2025$109.0KBeat by $19.7K
Q4 2024$151.0KBeat by $56.8K

Diluted EPS

Q1 2026-$0.18Miss by $0.05Q4 2025-$0.11Beat by $0.07Q3 2025-$0.17Beat by $0.03Q2 2025-$0.21Miss by $0.02Q1 2025-$0.20Miss by $0.01
Q4 2024-$0.21Beat by $0.05

Ask the moment Cardiff Oncology reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cardiff Oncology report Q4 2024 earnings?
Cardiff Oncology (CRDF) reported Q4 2024 earnings on February 27, 2025 after market close.
What were Cardiff Oncology's Q4 2024 revenue and EPS?
Cardiff Oncology reported revenue of $151.0K and diluted EPS of $-0.21 for Q4 2024.
Did Cardiff Oncology beat estimates in Q4 2024?
Revenue beat the consensus estimate of $94.2K by $56.8K. EPS beat the consensus estimate of $-0.26 by $0.05.
Where can I find Cardiff Oncology's Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-028992) directly on SEC EDGAR. The filing index links above go to sec.gov.